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ABSTRACT
Objective: Meningococcal disease occurs worldwide.
Approximately 1400 to 2800 cases are reported in the United
States annually. The goal of this analysis was to examine hos-
pitalized cases of meningitis and meningococcemia to iden-
tify case characteristics, resource use, and inpatient care
costs.
Methods: International Classiﬁcation of Diseases-9th Revi-
sion-Clinical Modiﬁcation diagnosis codes 036.0–036.9
were used to identify cases from roughly 1000 hospitals in
four all payer state discharge databases. Multiyear data
(1999–2001) were examined to identify demographics,
admission month, health service utilization, and hospital
costs by age group: infant (<1 years), children (1–10 years),
adolescent (11–17 years), young adult (18–22 years), adults
(23–49 years), and adults (≥50 years). Cost estimates include
accommodations, ancillary and physician services, reported
in 2003 US$.
Results: Of 1654 cases of meningococcal disease identiﬁed,
meningococcemia was coded for 51%. Adults accounted for
33% of the cases. The highest rate of admissions occurred
from January through March and 62% were admitted via the
Emergency Department. Inpatient case fatality rate was
6.4%; 71% of those who died had meningococcemia. The
mean length of stay was 9 days. Of survivors, 91% were dis-
charged home (1% with intravenous medications and 11%
with other home health-care services) while 7% required fur-
ther subacute inpatient care. The average cost per hospitali-
zation was estimated at $23,294 per patient. Infants had the
lowest average cost per stay ($16,793) and adolescents had
the highest ($28,202).
Conclusions: The presence of meningococcemia results in a
greater death rate, longer length of stay, and increased care
costs. Meningococcal disease has substantial economic, as
well as profound clinical consequences for patients of all
ages.
Keywords: costs, hospital care, meningitis, meningococcal
disease, meningococcemia, resource use.
Introduction
Use of conjugate vaccines for H. inﬂuenzae and S.
pneumoniae in the past decade [1,2] has substantially
reduced bacterial meningitis cases caused by these
organisms; however, meningococcal disease remains a
serious public health problem as it has severe, poten-
tially lethal, clinical consequences. Neisseria meningi-
tidis is now the leading cause of meningitis in children
and adults [3,4] in the United States. All ages are sus-
ceptible, but infants, children, and young adults are
particularly vulnerable [4,5]. N. meningitidis can be
categorized into 13 serogroups, 5 of which (i.e., A, B,
C, Y, W135) are reported to be the cause of almost all
meningococcal disease worldwide [6]. The annual
number of US cases of meningococcal disease has been
reported to be from 1400 to 3000 cases. The average
annual incidence has been estimated to be between 0.6
and 1.5 cases per 100,000 persons [7–11] with the
highest incidence reported for infants less than 1 year
[10]. Although meningococcal meningitis is most often
thought of as a disease of infants and young people, it
has been reported in recent years that more cases occur
in adults, aged 23 to 64 years, than in any other age
group [7].
Historically, routine administration of the quadri-
valent polysaccharide meningococcal vaccine for sero-
groups A, C, Y, and W135 has not been carried out in
the United States, except for high-risk groups (e.g.,
military, college freshmen living in dormitories) or dur-
ing outbreaks because of poor immunogenicity in
young children and a short span of protection. In
1997, The American College Health Association rec-
ommended that colleges institute vaccinations with the
existing quadrivalent polysaccharide meningococcal
vaccine and educational programs about the dangers
of meningitis for college freshman [12]. In 2005, a new
tetravalent conjugate vaccine for meningococcal dis-
ease with the potential for providing longer protection
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and better immunogenicity was approved for immuni-
zation of adolescents and adults, aged 11 to 55 years
by the US Federal Food and Drug Administration [13].
Availability of this new vaccine has prompted new
immunization recommendations for meningococcal
disease from the National Center for Infectious Dis-
eases’ Advisory Committee on Immunization Practices
[9] that will likely lead to initiation of immunization
programs for meningitis in the United States, similar to
those in Canada [7], Europe, and Australia.
When initiating a new vaccination program, rele-
vant decision-makers need to consider many factors,
such as efﬁcacy, safety, herd immunity, and cost. Hos-
pitalization costs are a major component of any health
economic analysis and patients diagnosed with menin-
gococcal disease receive inpatient care. Yet, published
information about hospital care for meningococcal
disease and the related cost is scarce. Thus, this anal-
ysis was performed to provide information heretofore
not reported regarding inpatient management of
meningococcal disease, including patient-level costs.
Materials and Methods
An examination of cases admitted to hospitals for
meningococcal disease in four states over a period of
3 years was undertaken for the purpose of identifying
case characteristics, seasonality of the admission,
resource use, and inpatient care costs overall and by
age group. The costs reported are meant to reﬂect the
economic value of the resources consumed, regardless
of who actually pays for them. Cases were analyzed by
age groups which were deﬁned for this analysis as fol-
lows: infants (<1 year), children (1–10 years), adoles-
cents (11–17 years), young adults (18–22 years),
adults (23–49 years), and older adults (≥50 years).
Several years of discharge data were examined to
obtain enough cases to establish representative cost
estimates. Hospital cases reported by roughly 1000
hospitals (i.e., community, teaching, pediatric) in Cal-
ifornia, Florida, Massachusetts, and Washington state
were identiﬁed from inpatient discharge databases
[14–17] for the years 1999 through 2001. These
claims databases, maintained by each individual state,
include case-level merged demographic, clinical, and
economic data. All ages and all payers are represented
in the data.
Admission for meningococcal disease was identiﬁed
using the International Classiﬁcation of Diseases-9th
Revision-Clinical Modiﬁcation (ICD-9) principal diag-
nosis codes 036.0 (meningococcal meningitis), 036.1
(meningococcal encephalopathy), 036.2 (meningococ-
cal septicemia), and 036.9 unspeciﬁed meningococcal
disease [18]. For this analysis, cases admitted for
meningococcal disease with a secondary diagnosis of
meningococcemia were grouped with the septicemia
cases. Serotypes cannot be identiﬁed in these data sets.
Cases with a secondary diagnosis of HIV/AIDS were
excluded from the analysis to avoid any potential inﬂu-
ence on cost estimates.
Acute hospital costs include all accommodations
(e.g., routine, intensive care unit [ICU] ), ancillary
services (e.g., pharmacy, laboratory), emergency
department (ED) and observation unit care prior to
admission where appropriate, and physician services.
An observation unit is a section of the hospital used for
further evaluation and treatment to determine the need
for possible admission to the hospital. Hospital costs
were obtained by direct data analysis of the state data-
bases. As physician-related costs are not included in
the discharge databases, it was necessary to develop
resource use proﬁles for inpatient physician services.
These population-speciﬁc proﬁles were based on
length of stay (LOS), procedure codes, special care unit
stays, prior to admission ED use, and other relevant
database elements. The appropriate Physicians’ Cur-
rent Procedural Terminology (CPT-4) code [19] was
assigned to each visit or procedure. A unit cost, repre-
sentative of multiple payers, established using fee
schedules and published payer ratios [20–22] was
applied to each CPT-4 code in this proﬁle.
Only direct medical costs reported in 2003 US$ are
included in the estimates. Older values were inﬂated
using rates based on the medical care component of the
US Consumer Price Index, supplied by the Federal
Bureau of Labor Statistics for the appropriate years
[23]. Hospital charges were adjusted to costs using a
0.61 cost-to-charge ratio. Where data from a single
state were used (i.e., Florida Medicaid physician fees),
state costs were adjusted to national values using ratios
based on published national and state cost data [24].
Washington state does not report either race or
ethnicity data; therefore, cases from that state were
assigned the label of “missing” for these data elements
for this analysis. The state databases do not contain
the actual date of admission or discharge, only the
month or quarter of admission and/or discharge are
released. To analyze admissions by season, month of
hospitalization, where reported, was collapsed into the
relevant quarter with January, February, and March as
the ﬁrst quarter.
Data from the Centers for Disease Control (CDC)
reports of notiﬁable diseases for the same years [25–
27] and from the 2000 US Census [28] were abstracted
and analyzed to understand how representative the
results of this analysis are to the United States as a
whole.
Results
A total of 1634 (52% male) cases admitted for menin-
gococcal disease due to N. meningitidis were identiﬁed
in the 1999–2001 state databases. These cases repre-
sent 23% of all US meningococcal disease cases
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reported by the CDC for those years [9]. Meningococ-
cemia (n = 826) was coded for roughly half (51%) of
the cases analyzed. Meningitis without septicemia
(n = 751) accounted for 46%, meningococcal enceph-
alopathy for 41 cases (2%) and unspeciﬁed meningo-
coccal disease for the remaining 16 cases (1%).
Because of the small number of cases reported for these
last two groups, they were not analyzed as distinct
populations. Thus, results by age group are reported
only for cases hospitalized with a principal diagnosis
of meningococcal meningitis (nonseptic) or meningo-
coccemia (septic). Case characteristics for septic and
nonseptic cases are reported in Table 1.
More than half (56%) of all meningococcal disease
cases in this analysis were admitted to California hos-
pitals, 23% Florida hospitals, 11% Massachusetts
hospitals, and 10% Washington hospitals. Almost all
cases were admitted from the community. Less than
1% were admitted from a nursing home, a residential
care or correctional facility. Prior to admission,
roughly two-thirds (62%) were seen in the ED, 1% in
an observation unit. The highest proportion (38%) of
all cases was hospitalized during winter and early
spring months (January–March); July through Septem-
ber had the fewest admissions. This overall pattern
was similar for septic and nonseptic cases, albeit a
larger proportion of the meningitis cases without sep-
sis was admitted January through March (Fig. 1), as
well as for most age groups (Fig. 2).
In 2001, California adopted the practice of ran-
domly masking some identifying variables (e.g., age,
race, sex, ethnicity) in different versions of their data
releases to protect patient conﬁdentiality [29]; there-
fore, age in years could not be determined for some
cases. The age value for these California cases was
labeled as missing for this analysis. Age was not
reported for 20% of study cases. The mean age for
cases where age was reported (n = 1300) was 24 years
(median: 17, range: 0–96 years).
The overall inpatient case fatality rate (CFR) was
6.4% (30% male, mean age: 34 years). Septic cases
accounted for 71% of the inpatient deaths. Patients
were hospitalized an average of 3 days at time of
death. The mean total LOS for all survivors was
8.8 days (median: 6.5), with those surviving septic
meningitis hospitalized 2 days longer, on average
(Table 2). Those (54%) receiving intensive care (ICU)
were hospitalized almost 2 days longer (mean ICU
LOS: 4.7 days, 45% of 10.4-day stay), on average.
The proportion of septic and nonseptic ICU cases was
similar; however, the average ICU LOS for septic cases
was longer (mean ICU LOS: 5.3 days) than for non-
septic cases (mean ICU LOS: 2.7 days). Patients dis-
charged alive who had meningococcemia had a higher
Table 1 Case characteristics by diagnosis
Meningitis
(ICD-9 code:
036.0)
Meningococcemia 
(ICD-9
code: 036.2)
Cases (n) 751 826
Male (%) 54 51
Mean age (years) 23 24
Age distribution (%)
Infants (<1 year) 6 5
Children (1–10 years) 17 26
Adolescents (11–17 years) 13 10
Young Adults (18–22 years) 13 9
Adults (23–49 years) 22 17
Adults (≥50 years) 11 15
Missing/not stated 18 18
Race (%)
White 59 59
Black 9 6
Asian 3 3
Native American 1 <1
Other 5 7
Missing/not stated 23 24
Ethnicity (%)
Hispanic 16 17
Not Hispanic 61 61
Not stated 23 22
ICD-9, International Classiﬁcation of Diseases-9th Revision-Clinical Modiﬁcation.
Figure 1 Seasonality of hospitalization for meningococcal disease cases
(all ages) by septic status.
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rate of transfer to postacute care facilities than those
with meningitis without sepsis (Fig. 3).
The mean cost of a hospital stay was estimated to
be $23,294 per person when all meningococcal disease
cases were examined (median: $11,644). Survivors
with sepsis accrued roughly $10,000 more per stay, on
average than those without sepsis. A cost increase,
albeit smaller, was seen among inpatient fatalities as
well (Table 2). Managed care organizations (e.g.,
health maintenance organizations, preferred provider
organizations) and Medicaid, a government-funded
health plan for qualiﬁed persons with low income,
were the two most prevalent primary payers (Table 3).
Workers’ compensation insurance was noted for 1%
of the adult patients, but the occupation of these
patients is not known. Less than 1% of all cases had
payer data missing.
Cases Analyzed by Age
Adults accounted for one-third of meningococcal dis-
ease admissions analyzed (n = 514, 51% male, mean
age: 48 years, range: 23–96 years). Most adults (60%)
were in the age group of 22 to 49 years. Children were
the next largest group (n = 342, 53% male, mean age:
3.7 years), followed by adolescents (n = 180, 54%
males, mean age: 14.6 years), young adults (n = 175,
60% male, mean age: 19 years), and infants (n = 99,
56% male). The rate of septic cases ranged from 43%
in young adults to 63% in children (Table 4). The pro-
portion of men (64%) reported in nonseptic infant
cases (n = 45) was higher than observed for septic
infant cases, or for those of any other age group. It
could not be determined if this elevated rate of male
infants was in keeping with nonstudy hospitalized
infants, as the CDC reported infant data by age or gen-
der, not age and gender.
Adolescents had the lowest rate (44%) of ED care
prior to admission; adults had the highest rate (83%).
Thirteen children with septic meningitis accounted for
all preadmission observation unit stays. The average
LOS ranged from 7.8 days for those of college age to
9.2 days for older adults. On average, infants had the
lowest cost per stay (mean: $16,793) and adolescents
had the highest (mean: $28,202). The mean cost per
Table 2 Meningococcal disease inpatient case fatality, LOS, and
cost per stay by diagnosis
Meningitis
(ICD-9 code:
036.0)
Meningococcemia
(ICD-9 code:
036.2)
All cases (n) 751 826
Inpatient case fatality rate (%) 4 9
Mean age (years)
Fatal cases 29 31
Nonfatal cases 23 23
Mean LOS (days)
Fatal cases 2.5 3.3
Nonfatal cases 7.7 9.6
Cost of stay: fatal cases ($)
Mean 17,113 22,800
Median 11,180 8,144
Cost of stay: nonfatal cases ($)
Mean 17,394 27,903
Median 12,145 11,462
ICD-9, International Classiﬁcation of Diseases-9th Revision-Clinical Modiﬁcation;
LOS, length of stay.
Figure 3 Discharge disposition for hospital stay survivors for all menin-
gococcal disease cases, by diagnosis and by age group. *Subacute facility
includes rehabilitation hospital, skilled nursing, intermediate and long-
term care facilities. HHC, home health-care services; SAF, subacute
facility.
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Table 3 Primary responsible payer for hospital costs for all cases and by age group
Primary payer
(% cases)
All cases 
(n = 1634)
Infants
(n = 99)
Children
(n = 342)
Adolescents
(n = 180)
Young adults 
(n = 175)
Adults 
(n = 514)
Managed care 42 33 34 61 51 33
Medicaid 28 59 48 12 12 12
Medicare 6 0 0 0 0 25
CI/BC 12 2 12 16 20 9
Other Gov. 1 1 0 0 0 2
WC <1 0 0 0 0 1
Other* 10 5 6 11 17 16
Missing <1 0 0 0 0 2
*Other payer category includes self-pay, charity, free care and indigent person.
BC, Blue Cross; CI, commercial insurer; Gov., government; WC, workers’ compensation.
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stay for other age groups was $27,100 for 22- to 49-
year-old adults, $26,262 for young adults, $21,400 for
adults of 50 years and older, and $20,284 for children.
Patients with sepsis in age groups other than infants
and older adults were hospitalized 2 to 3 days longer,
on average than those without sepsis. In all age groups,
the cost per stay for septic cases was greater than non-
septic cases; however, septicemia appears to have the
least impact on infant care costs (Table 3). As all
infants spent time in either an intensive care nursery or
a pediatric ICU, the uniformity of level and location of
care may have muted the cost differences seen in other
age groups.
In all age groups, the majority of survivors were dis-
charged home, albeit more, older adults were trans-
ferred for postacute care than younger patients
(Fig. 3). A small percentage (1–2%) of patients in all
age groups but older adults was discharged home on
intravenous (IV) medications. In the adult age group of
22 to 49 years, two patients signed out against medical
advice and three were returned to a correctional
facility.
Total Cost of Hospital Care
The cumulative cost over 3 years for all meningococcal
disease cases examined in this study was estimated to
be approximately $41.6 million. When this is exam-
ined by year, the average annual cumulative cost was
$13.9 million. The number of cases in 1 year of our 3-
year analysis ranged from 527 to 562.
For the same years studied in this analysis (1999–
2001), the number of US cases of meningococcal dis-
ease reported by the CDC ranged from 2256 to 2501;
however, this number dropped to 1814 in 2002 [30],
and to 1756 in 2003 [9]. By applying the average cost
per case calculated for our analysis to the average of
the number of annual reported US cases for the period
from 1999 to 2003, a total cost for acute inpatient
management of meningococcal disease in the United
States was estimated to be $49.7 million for 1 year
(range from $40.9 million for the year with fewest
cases reported to $58.3 million for the year with the
highest number).
Discussion
The incidence of meningococcal disease varies broadly
from one US state to another, and among regions of the
country [7]. The data used in this analysis were
reported by approximately 1000 acute care hospitals
from four geographically diverse states. Although
these hospitals represent almost one quarter of all
those operating in the United States during that period
[31], the question of how representative the study
cases are needs to be considered. An examination of
CDC reported data for meningococcal disease cases
(n = 7090) during the same 3-year period [25–27]
revealed a similar admission pattern with regard to
hospitalization month. Differences were noted in some
age groups, race, and ethnicity. Our sample underrep-
resents infants (6% vs. 12% for CDC cases), adults
over 65 years (8% vs. 14% for CDC cases), and those
whose race is recorded as black (8% vs. 15% for CDC
cases). Conversely, the study sample has a higher pro-
portion of those noted to be Hispanic (17% vs. 10%
for CDC cases) or Asian (3% vs. 2% for CDC cases).
To understand these differences better, we examined
data pertaining to age, sex, race, and ethnicity from the
2000 US Census [31]. The proportion of residents by
age and sex in the analysis-relevant states was almost
identical when compared with the United States as a
whole; however, the proportion of those over 65 years
old was slightly higher in the selected states (13% vs.
12% for United States). Thus, the make-up of resident
populations does not explain why there would be a
lower incidence among infants and those over 65 years
in the study cases compared with the CDC data. The
three states in our analysis that reported data had
fewer black (8% vs. 12% for United States), more
Asian (8% vs. 4% for United States), and more His-
panic (25% vs. 13% for United States) residents. Thus,
local characteristics could explain race and ethnicity
differences with CDC cases; but the age differences are
more likely a result of missing or unreported age data
in the study sample. Men represented 51% of the
meningococcal disease cases reported by the CDC for
years 1999 to 2001. This is comparable to the rate seen
in our all case sample for the same years; however, as
Table 4 LOS (days) and case costs ($) by age group for septic and nonseptic cases
Meningitis (ICD-9 code: 036.0) Meningococcemia (ICD-9 code: 036.2)
Cases Mean LOS (Median) Mean cost (Median) Cases Mean LOS (Median) Mean cost (Median)
All cases 751 7.5 (7.0) 17,399 (12,038) 826 9.2 (6.0) 27,540 (10,953)
Infants (<1 year) 45 8.6 (7.8) 16,254 (12,152) 44 7.5 (5.5) 17,344 (7,642)
Children (1–10 years) 126 6.2 (6.5) 10,059 (8,587) 216 9.3 (6.0) 26,248 (10,106)
Adolescents (11–17 years) 94 7.0 (6.8) 17,793 (12,615) 86 10.3 (6.5) 34,274 (12,995)
Young adults (18–22 years) 100 6.8 (6.3) 17,899 (10,893) 75 9.1 (6.0) 37,412 (15,098)
Adults (23–49 years) 167 8.3 (8.7) 21,378 (14,267) 139 10.2 (6.0) 33,954 (14,943)
Adults (≥50 years) 84 9.0 (8.5) 20,564 (18,668) 124 8.8 (6.8) 21,929 (12,944)
NB: Summing of cases in the age groups will not equal the all cases ﬁgure as some cases did not report age.
ICD-9, International Classiﬁcation of Diseases-9th Revision-Clinical Modiﬁcation; LOS, length of stay.
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noted previously, some variation in the rate by age
group was observed in the study cases, but a compar-
ison could not be made to see if the age-speciﬁc gender
rates were atypical, as gender by age data were not
reported by the CDC.
The hospital CFR for patients with meningococcal
disease in the study was 6%, lower than the 9% to
21% reported in the literature [7,32]. As many factors
(e.g., clinical severity, timeliness, and quality of care)
could play a role in lower hospital fatality rates for the
study cases, an exact reason cannot be determined
based on the available data; however, fewer older
adults is a factor, as they had the highest CFR (10%) in
our analysis.
The use of discharge databases for case accounting
raises a concern about potential coding errors. The
coding error rate in the state databases for meningo-
coccal disease is unknown, but it is common for an
infectious disease to be identiﬁed with less speciﬁc
codes [33]. It is possible that some cases caused by
N. meningitides were coded under a generic bacterial
meningitis diagnosis code (e.g., ICD-9 code 320.9—
meningitis caused by unspeciﬁed organism). This could
explain the lower than expected number of cases and
CFR for some age groups. Conversely, basing the anal-
ysis on cases identiﬁed by principal diagnosis—deﬁned
as the chief reason determined after review for admis-
sion to the hospital—may provide more accurate infor-
mation. Case statistics published by the CDC are based
on reported, not conﬁrmed cases. In 2000, the number
of reported cases, on which the CDC statistics were
based was 2256, but only 1808 (80%) were conﬁrmed
to be meningococcal disease [25]. As statistics regard-
ing age, gender, race, ethnicity, and CFR were not pro-
vided for conﬁrmed cases, it is impossible to determine
if the conﬁrmed case proﬁles would  match  those  of
all  CDC  reported  cases  or would be more in keeping
with the cases in our analysis.
Data examined in this study reinforce previously
noted [7] seasonal increases in the occurrence of
meningococcal meningitis. Most hospitalizations took
place in the winter and early spring across the years
examined and in all states, even though the four states
(i.e., California, Florida, Massachusetts, Washington)
are climatically diverse during these months.
Children were the largest group of cases in this
analysis, had the highest percentage of septic cases,
and were the only ones to spend time in an observation
unit prior to admission. The reason for preadmission
observation cannot be determined from study data. As
the incidence of meningococcal disease is known to
decline between infancy and adolescence [7], meningi-
tis may not be at the forefront of clinicians’ differential
diagnoses for a child presenting with early symptoms
of an infectious disease. Increased education may be
warranted to heighten awareness of the potential for
this disease, particularly for physicians seeing young
patients in areas outside the usual pediatric environ-
ment, such as the ED.
Containment of health-care expenses is a concern in
the United States and elsewhere. Increasingly, there has
been an effort to manage cases, when possible, as out-
patients. Traditionally, life-threatening diseases like
meningococcal meningitis are managed acutely in hos-
pitals. Yet, there has been some movement noted by
the American Academy of Pediatrics [34,35] over the
past decade to provide at home the last few days of IV
antibiotic therapy for stable patients. Some evidence of
this was seen in our study, though few (1%), dis-
charges home on IV medications were seen in all age
groups except older adults.
Despite the rarity of hospitalizations for meningo-
coccal disease in the United States, their high cost
translates to an annual economic burden of almost $50
million. This is comparable to the economic burden of
varicella-related hospitalizations observed in the post-
vaccine era, where annual charges have been estimated
at $66.3 million in 2001, although much lower than
the 1993 reported charges [36] of $161.1 million
(equivalent to $238.8 million in 2003 US$) in the pre-
vaccine era. Costs, however, are signiﬁcantly lower
than for more common infectious disease hospitaliza-
tions. For example, the cost of all encephalitis-
associated hospitalizations (more than 70% of which
had viral or other infectious causes) has been reported
[37] in 1997 US$ values at $650 million ($817 million
in 2003 US$), with an average cost per hospitalization
of $28,151 ($35,375 in 2003 US$). Intestinal infec-
tious diseases led to roughly a quarter of a million
hospitalizations in 1985 in the United States at an
estimated cost of $650 million [38] ($1.7 billion in
2003 US$), while annual hospitalization charges for
respiratory syncytial virus pneumonia have been esti-
mated at between $300 and $400 million, as a result of
16,000 to 21,000 hospitalizations annually [39].
As noted previously, the approval of and recom-
mendations for use of the new tetravalent conjugate
vaccine will likely increase the number of US vaccina-
tions. The impact of vaccination on meningococcal
disease hospitalization costs is difﬁcult to quantify,
and dependent on who is vaccinated, the efﬁcacy of
the vaccine, and the indirect beneﬁts, or herd immu-
nity, resulting from vaccination [40]. A recent cost-
effectiveness evaluation of conjugate meningococcal
vaccination strategies in the United States predicted
that for a single cohort of individuals targeted for
vaccination, between 270 and 447 cases would be
avoided over 22 years [41]. At a mean cost per hospi-
talization of $23,294, this translates to savings of $6
to $10 million. This study, however, looked at only
cases of meningococcal disease within the targeted
cohort, and did not take into consideration any herd
immunity. A more comprehensive economic analysis,
which looked at cases in the entire US population,
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and did account for herd immunity, estimated that
targeting 12 years olds for vaccination with a quadri-
valent conjugate vaccine would eventually reduce the
number of cases in the United States by more than
1000 per year [42]. Under this scenario, routine vac-
cination of adolescents in the United States, as
currently recommended by the CDC’s Advisory Com-
mittee on Immunization Practices [43], would lead to
savings in hospital costs of roughly $25 million per
year.
Conclusions
Patients with meningococcemia have a higher death
rate, a longer LOS and accrue more costs, on average
than patients with meningitis without septicemia.
Because of the lower incidence of meningitis, the eco-
nomic burden of this problem may not be as great as
the cost seen for more common infectious diseases;
nevertheless, there are economic consequences that
need to be quantiﬁed and understood. The data pro-
vided in this study show that this disease occurs irre-
spective of age, affecting infants to those over 90 years.
This study shows that several millions of dollars are
spent annually on hospital care for patients who have
this clinical problem. Managed care organizations and
government insurers, such as Medicaid, bear the bulk
of the direct cost burden. Furthermore, the cost of hos-
pital care reﬂects only one component of the economic
picture as patients will require follow-up care with
their usual care physician and some, as evidenced by
the disposition data, will receive additional postacute
care in the form of home health, rehabilitative and sub-
acute care.
The results reported in this analysis provide disease-
speciﬁc resource use and cost data by age. Apart from
clinicians, who are responsible for the care and well-
being of patients with this serious condition, those
concerned with the economic aspects of treating
meningococcal disease, such as key payer groups, like
managed care organizations and Medicaid, also have a
vested interest in understanding the economic ramiﬁ-
cations of meningococcal disease-related care. In addi-
tion, policy decision-makers and researchers, who
must consider economic issues regarding vaccination
programs and weigh the cost, should ﬁnd these results
helpful in furthering their understanding of the eco-
nomic burden of meningococcal disease.
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